---
document_datetime: 2025-07-15 12:57:17
document_pages: 9
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/calquence-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: calquence-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 5.572049
conversion_datetime: 2025-12-14 16:23:28.01825
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## Calquence

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                                                        | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                   |
|----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|---------------------------------------------------------------------------|
| II/0028              | Extension of indication to include CALQUENCE in combination with venetoclax with or without obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL), based on interim results from study AMPLIFY (D8221C00001); this is a randomised, | 25/04/2025                          | 02/06/2025                                  | SmPC and PL                      | Please refer to Scientific Discussion ''Calquence- EMEA/H/C/005299/II/28' |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|         | multicentre, open-label, phase 3 study of acalabrutinib in combination with venetoclax with and without obinutuzumab compared to investigator's choice of chemoimmunotherapy in subjects with previously untreated CLL without del(17p) or TP53 Mutation. As a consequence, sections 4.1, 4.2, 4.4, 4.8, and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 8.2 of the RMP was also submitted. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one                                                                                                                                                                      |            |            |             |                                                                            |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|----------------------------------------------------------------------------|
| II/0026 | Extension of indication to include CALQUENCE as monotherapy for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy based on final results from study ACE-LY-004 (D8225C00002); this is an open- label, phase 2 study of ACP-196 in subjects with Mantle Cell Lymphoma. As a consequence, sections 4.1 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 7.2 of the RMP has also been submitted. In addition, the MAH took the opportunity to introduce minor editorial and formatting changes to the PI. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | 27/02/2025 | 02/05/2025 | SmPC and PL | Please refer to Scientific Discussion 'Calquence- EMEA/H/C/005299/II/0026' |

<div style=\"page-break-after: always\"></div>

| II/0025   | Extension of indication to include Calquence in combination withbendamustineand rituximab (BR) as treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are not eligible for autologous stem cell transplant (ASCT) based on interim results from study ACE-LY-308 (ECHO, D8220C00004); this is a Phase III, randomized, double-blind, placebo-controlled, multicenter study of BR alone versus in combination with acalabrutinib (ACP-196) in subjects with previously untreated MCL. As a consequence, sections 4.1, 4.2, 4.4, 4.8, and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 6, succession 2 of the RMP has also been submitted. In addition, the MAH took the opportunity to implement editorial changes to the SmPC. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or   | 27/03/2025   | 02/05/2025   | SmPC and PL   | Please refer to Scientific Discussion ''Calquence- EMEA/H/C/005299/II/25'   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|---------------|-----------------------------------------------------------------------------|
| IB/0027/G | This was an application for a group of variations. B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 31/10/2024   | n/a          |               |                                                                             |

<div style=\"page-break-after: always\"></div>

|                     | Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation                                                                                                                                                                                                              |            |            |    |                                                                                                                        |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----|------------------------------------------------------------------------------------------------------------------------|
| IB/0024/G           | This was an application for a group of variations. B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch- release, batch control, primary and secondary packaging, for non-sterile medicinal products | 14/06/2024 | n/a        |    |                                                                                                                        |
| PSUSA/10887 /202310 | Periodic Safety Update EU Single assessment - acalabrutinib                                                                                                                                                                                                                                                                                                                                                                                                             | 16/05/2024 | n/a        |    | PRAC Recommendation - maintenance                                                                                      |
| IB/0023             | B.II.d.1.c - Change in the specification parameters and/or limits of the finished product - Addition of a new specification parameter to the specification with its corresponding test method                                                                                                                                                                                                                                                                           | 14/05/2024 | n/a        |    |                                                                                                                        |
| N/0022              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                        | 16/02/2024 | 02/05/2025 | PL |                                                                                                                        |
| PSUSA/10887 /202210 | Periodic Safety Update EU Single assessment - acalabrutinib                                                                                                                                                                                                                                                                                                                                                                                                             | 22/06/2023 | 16/08/2023 |    | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for |

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                                                                                                                                         |            |            |                 | PSUSA/10887/202210.                                                           |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|-------------------------------------------------------------------------------|
| IB/0019   | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                                                                                                                                                                                                                                  | 21/06/2023 | n/a        |                 |                                                                               |
| IB/0020   | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                                                                                                                                                                                               | 14/06/2023 | 16/08/2023 | SmPC            |                                                                               |
| IA/0018   | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                            | 26/05/2023 | n/a        |                 |                                                                               |
| II/0015   | Update of section 5.1 of the SmPC based on the interim report of study ACE-CL-007; a randomized, multicenter, open-Label, 3-arm phase 3 study of obinutuzumab in combination with chlorambucil, ACP-196 in combination with obinutuzumab, and ACP-196 monotherapy in subjects with previously untreated chronic lymphocytic leukemia. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 12/05/2023 | 16/08/2023 | SmPC            | For more information, please refer to the Summary of Product Characteristics. |
| IAIN/0017 | A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release                                                                                                                                                                                                                                                                                                                              | 03/05/2023 | 16/08/2023 | Annex II and PL |                                                                               |
| X/0009/G  | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                      | 15/12/2022 | 20/02/2023 | SmPC,           |                                                                               |

<div style=\"page-break-after: always\"></div>

|                     | Annex I_2.(d) Change or addition of a new pharmaceutical form A.6 - Administrative change - Change in ATC Code/ATC Vet Code                                                                                                                                                                                                                                                                                                                                    |            |            | Labelling and PL   |                                                                               |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|--------------------|-------------------------------------------------------------------------------|
| II/0013             | Update of section 5.1 of the SmPC in order to update efficacy and safety information based on final results from study ACE-CL-309 (A Phase 3 randomized open-label active-control study investigating Calquence for the Treatment of Subjects With Relapsed or Refractory Chronic Lymphocytic Leukaemia) listed as a category 3 study in the RMP. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance | 12/01/2023 | 16/08/2023 | SmPC               | For more information, please refer to the Summary of Product Characteristics. |
| PSUSA/10887 /202204 | Periodic Safety Update EU Single assessment - acalabrutinib                                                                                                                                                                                                                                                                                                                                                                                                    | 01/12/2022 | n/a        |                    | PRAC Recommendation - maintenance                                             |
| PSUSA/10887 /202110 | Periodic Safety Update EU Single assessment - acalabrutinib                                                                                                                                                                                                                                                                                                                                                                                                    | 10/06/2022 | n/a        |                    | PRAC Recommendation - maintenance                                             |
| II/0011             | Submission of an updated RMP version 3 in order to add hepatotoxicity as an important potential risk to the safety concerns. C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated                                                                                                                               | 13/01/2022 | n/a        |                    | Not applicable.                                                               |

<div style=\"page-break-after: always\"></div>

|                     | by new additional data to be submitted by the MAH where significant assessment is required                                                                                                                                                                                                                                                                                                                                                                     |            |            |      |                                                                                                                                                                                                                                                                                                                                                                                              |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10887 /202104 | Periodic Safety Update EU Single assessment - acalabrutinib                                                                                                                                                                                                                                                                                                                                                                                                    | 02/12/2021 | n/a        |      | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                            |
| II/0004             | Submission of the final report of the nonclinical Study 20266648 (5336BV) (Acalabrutinib: Neutral Red Uptake Phototoxicity Assay in BALB/c 3T3 Mouse Fibroblasts), in response to the CHMP recommendation to submit results from a modified 3T3 NRU phototoxicity study with adjusted wavelengths. SmPC sections 4.4 and 5.3 were updated accordingly. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission | 11/11/2021 | 08/07/2022 | SmPC | For more information, please refer to the Summary of Product Characteristics.                                                                                                                                                                                                                                                                                                                |
| IA/0010             | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                                                                                                                                                                   | 21/10/2021 | n/a        |      |                                                                                                                                                                                                                                                                                                                                                                                              |
| II/0007             | Update of section 4.5 of the SmPC following submission of the final report from ACE-HV-114, an open-label, fixed sequence study in healthy subjects to assess the pharmacokinetics of acalabrutinib and its active metabolite, ACP-5862, when administered alone and in combination with moderate CYP3A4 inhibitors fluconazole or isavuconazole.                                                                                                              | 30/09/2021 | 08/07/2022 | SmPC | Small increases in acalabrutinib maximum concentration (Cmax) and Area Under the Curve (AUC) and decreases of the Cmax and AUC of its active metabolite ACP-5862 were obserevd when acalabrutinib was co-administed with moderate CYP3A inhibitors in helathy subjects. No dose adjustment of acalabrutinib is required when used in combination with moderate CYP3A inhibitors but patients |

<div style=\"page-break-after: always\"></div>

|           | In addition, the MAH took the opportunity to bring the PI in line with the latest QRD template version 10.2. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                           |            |            |      | should be monitored closely for adverse reactions.   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|------------------------------------------------------|
| II/0006   | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                                                                        | 30/09/2021 | n/a        |      |                                                      |
| II/0005   | Submission of the final report from study XS-1468 to further characterise the plasma protein binding of acalabrutinib and its metabolite ACP-5862 in different species. Section 5.2 of the SmPC is updated accordingly to reflect the new plasma protein binding data. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority | 24/06/2021 | 08/07/2022 | SmPC |                                                      |
| IAIN/0003 | C.I.11.a - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of wording agreed by the competent authority                                                                                                                                                                                                                            | 18/02/2021 | n/a        |      |                                                      |
| IA/0002   | B.III.1.b.3 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Updated certificate from an already approved manufacturer                                                                                                                                                                                                                                                         | 07/01/2021 | n/a        |      |                                                      |

<div style=\"page-break-after: always\"></div>

| IAIN/0001   | B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same   | 21/12/2020   | n/a   |
|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|